Project Grant R01AI193334
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $393K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), with a CFDA number of 93.855, provides $314,347 in funding to Gateway Bio Inc. for the period from September 23, 2025 to August 31, 2026. The project aims to develop a new lipid nanoparticle (LNP) delivery system for mRNA payloads that uses a proprietary polyethylene glycol (PEG) alternative called POEGMA. This novel LNP is intended to address concerns around PEG-related allergies and reduced...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $693,465 to Cornell University on January 21, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The funding will support a research project titled "Mapping Infant and Adult T Cell Immunity" that aims to construct the first molecular atlas of T cell development in lymph nodes and determine how cellular interactions and communication networks...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $806,208 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Weill Medical College of Cornell University. The project, titled "Spatial Omics to Understanding HBV Control in People with HIV Coinfection," will leverage cutting-edge spatial proteomic and transcriptomic technologies to analyze the impact of HIV-related immune suppression and restoration on the...
- This $3,170,096 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to develop the L7AE protein as a therapeutic for treating infections caused by the Orthomyxoviridae virus family, which includes influenza. The key research aims are: (1) investigating the mechanism of action of L7AE on various Orthomyxoviridae family members, (2)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $184,896 Project Grant to The Children's Hospital of Philadelphia (CHOP) to evaluate the potential of mRNA-lipid nanoparticle (mRNA-LNP) vaccines and lipid nanoparticle (LNP) adjuvants to overcome maternal antibody interference in infant vaccine responses. This research aims to address the challenge of effectively inducing protective antibody responses in young infants, who currently rely on maternal antibodies...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to characterize the mechanisms by which lipid nanoparticle (LNP) formulations induce immune responses, with the goal of enhancing LNP-based anti-tumor therapies. The $128,736 award to the Icahn School of Medicine at Mount Sinai will be used over a 2.5 year period from Dec 2024 to Jul 2027 to investigate how LNP properties and targeting influence their interactions with dendritic...
- The National Institute of General Medical Sciences (NIGMS) awarded a $365,616 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Gettysburg College, a private non-profit educational institution in Pennsylvania. The funding will support the development of a library of triazine-based, ionizable lipids that can be used to form lipid nanoparticles (LNPs) for delivering RNA into cells. The project aims to establish a structure-activity relationship (SAR)...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- The federal Project Grant award of $3,204,624.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, supports research to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The research aims to provide essential insight for developing improved therapeutics to reduce human sepsis, as well as immune adjuvants to enhance host...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $437,477 to New York University (NYU) to develop a human lymph node-on-a-chip microphysiological system for evaluating the effectiveness of vaccines against infectious diseases. The goal is to create a reliable in vitro model of human lymph nodes that can accurately replicate the immune response process and dynamics,...